Cassava Sciences Reports Material Definitive Agreement on Jan 3

Ticker: FLNA · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1069530

Cassava Sciences INC 8-K Filing Summary
FieldDetail
CompanyCassava Sciences INC (FLNA)
Form Type8-K
Filed DateJan 3, 2024
Risk Levelmedium
Pages6
Reading Time7 min
Key Dollar Amounts$0.001, $33.00, $0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: material-agreement, corporate-action, regulatory-filing

TL;DR

**Cassava Sciences just signed a big deal, details pending, could move the stock.**

AI Summary

Cassava Sciences, Inc. filed an 8-K on January 3, 2024, to report an "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits." This filing indicates that the company has entered into a significant new contract or arrangement. For investors, this matters because material agreements can significantly impact a company's future revenue, expenses, strategic direction, or even its ability to operate, potentially leading to stock price volatility depending on the nature and terms of the agreement.

Why It Matters

This filing signals a new, important business arrangement for Cassava Sciences, which could affect its financial performance and strategic outlook. Investors should monitor for details of this agreement to understand its potential impact on the company's value.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its financial implications and potential risks or benefits.

Analyst Insight

A smart investor would await further details on the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks the specifics needed to assess its impact on Cassava Sciences' financials or strategic position.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of Cassava Sciences, Inc.'s 8-K filing on January 3, 2024?

The primary purpose of Cassava Sciences, Inc.'s 8-K filing on January 3, 2024, is to report an "Entry into a Material Definitive Agreement" and to include "Financial Statements and Exhibits" related to this event.

What is the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 3, 2024, which is the date of the "Entry into a Material Definitive Agreement."

Where are Cassava Sciences, Inc.'s principal executive offices located?

Cassava Sciences, Inc.'s principal executive offices are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.

What is the par value of Cassava Sciences, Inc.'s Common Stock?

The par value of Cassava Sciences, Inc.'s Common Stock is $0.001 per share.

Under which SEC Act is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 1,715 words · 7 min read · ~6 pages · Grade level 12.1 · Accepted 2024-01-03 09:10:10

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6801 N Capital of Texas Highway , Building 1; Suite 300 Austin , Texas 78731 (Address of Principal Executive Offices) (Zip Code) (512) 501-2444 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into Material Definitive Agreement. On December 12, 2023, Cassava Sciences, Inc., a Delaware corporation (the " Company "), announced that the Board of Directors of the Company declared a distribution (the " Warrant Distribution ") to the holders of record of the Company's shares of common stock, par value $0.001 per share (the " Common Stock "), in the form of warrants to purchase shares of Common Stock (the " Warrants "). The Warrants were issued on the terms and conditions described in the Warrant Agreement (as defined below and attached as an exhibit hereto) and are being distributed on January 3, 2024, to the holders of record of Common Stock as of the close of business on December 22, 2023 (the " Record Date "). Pursuant to the terms of the Warrant Agreement, dated as of January 3, 2024, between the Company, Computershare Inc., a Delaware corporation, and its affiliate Computershare Trust Company, N.A., as Warrant Agent (the " Warrant Agreement "), each holder of record of Common Stock as of the Record Date will receive four Warrants for every ten shares of Common Stock (rounded down to the nearest whole number for any fractional Warrant). Each Warrant will entitle the holder to purchase, at the holder's sole expense and exclusive election, at an Exercise Price of $33.00 per Warrant, one share of Common Stock plus, to the extent described below, the Bonus Share Fraction. Payment for shares of Common Stock upon exercise of Warrants must be in cash. A Bonus Share Fraction entitles a holder to receive an additional 0.5 of a share of Common Stock for each Warrant exercised (the " Bonus Share Fraction ") without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time (the " Bonus Share Expiration Date ") upon the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period (commencing on or after January 3, 2024) in which the daily volume weighted average price (the " VWAP ") of the shares of Common Stock has been at the then applicable trigger price for at least 20 trading days (whether or not consecutive) (the " Bonus Price Condition ") and (ii) the date specified by the Company upon not less than 20 business days' public notice. Any Warrant exercised with an exercise date after the Bonus Share Fraction Expiration Date will not be entitled to the Bonus Share Fraction. The Registrant will make a public announcement of the Bonus Share Expiration Date (i) at least 20 business days prior to such date, in the case of the Registrant setting a Bonus Share Expiration Date and (ii) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition. Unless earlier redeemed, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on November 15, 2024 (the " Expiration Date "). The Warrants are redeemable at the

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing